Autophosphorylation of type I receptor tyrosine kinases (RTKs) comprises one step in the signaling events mediated by erbB receptors such as p185 neu and EGFR. Previous analysis of p185 neu has indicated that there are at least ®ve tyrosine autophosphorylation sites, Y882, Y1028, Y1143, Y1226/7 and Y1253, of which Y882 might be important because of its location in the kinase activity domain. We have speci®cally analysed the eect of a Y882F (phenylalanine substituted for tyrosine at position 882) mutation in the enzymatic active domain. We also deleted the carboxyl terminal 122 amino acids which contained three other autophosphorylation sites (TAPstop) and combined mutants of that deletion with Y882F (Y882F/APstop). Both in vitro and in vivo transformation assays showed that substitution of tyrosine 882 by phenylalanine signi®cantly decreased the transforming potential of activated, oncogenic p185 neu , although no signi®cant dierence in the total phosphotyrosine levels of the mutant proteins were observed. To analyse mitogenic signaling in response to ligand, the intracellular domains of p185 neu and Y882F were fused with the extracellular domain of the EGF receptor. The proliferation of cells expressing these chimeric receptors was EGF-dependent, and cells expressing EGFR/Y882F chimeric receptors were less responsive to EGF stimulation than those expressing EGFR/neu receptors. In vitro kinase assays demonstrated that abolishing the autophosphorylation site Y882 diminished the enzymatic tyrosine kinase activity of p185 neu . These studies, taken together with the phenotypic inhibition observed with cells expressing Y882F, suggest that the tyrosine 882 residue may be important for p185 neu -mediated transformation by aecting the enzymatic kinase function of the p185 neu receptor.
Autophosphorylation of type I receptor tyrosine kinases (RTKs) comprises one step in the signaling events mediated by erbB receptors such as p185 neu and EGFR. Previous analysis of p185 neu has indicated that there are at least ®ve tyrosine autophosphorylation sites, Y882, Y1028, Y1143, Y1226/7 and Y1253, of which Y882 might be important because of its location in the kinase activity domain. We have speci®cally analysed the eect of a Y882F (phenylalanine substituted for tyrosine at position 882) mutation in the enzymatic active domain. We also deleted the carboxyl terminal 122 amino acids which contained three other autophosphorylation sites (TAPstop) and combined mutants of that deletion with Y882F (Y882F/APstop). Both in vitro and in vivo transformation assays showed that substitution of tyrosine 882 by phenylalanine signi®cantly decreased the transforming potential of activated, oncogenic p185 neu , although no signi®cant dierence in the total phosphotyrosine levels of the mutant proteins were observed. To analyse mitogenic signaling in response to ligand, the intracellular domains of p185 neu and Y882F were fused with the extracellular domain of the EGF receptor. The proliferation of cells expressing these chimeric receptors was EGF-dependent, and cells expressing EGFR/Y882F chimeric receptors were less responsive to EGF stimulation than those expressing EGFR/neu receptors. In vitro kinase assays demonstrated that abolishing the autophosphorylation site Y882 diminished the enzymatic tyrosine kinase activity of p185 neu . These studies, taken together with the phenotypic inhibition observed with cells expressing Y882F, suggest that the tyrosine 882 residue may be important for p185 neu -mediated transformation by aecting the enzymatic kinase function of the p185 Introduction Activation of erbB receptor tyrosine kinases, such as p185 neu and the EGFR, involves oligomerization of receptors (reviewed in Heldin, 1995) . Mutation and overexpression of erbB family receptors has been found to lead to receptor activation by inducing the formation of dimeric and oligomeric forms (Weiner et al., 1989; Samanta et al., 1994) . The net eects of oligomerization are both enhanced kinase activity and subsequent signal transduction . Activation of erbB family receptors results in selfphosphorylation of receptors by an intermolecular mechanism and in the phosphorylation of substrates which are critical in initiating signal transduction events required for cell growth and dierentiation (Ullrich and Schlessinger, 1990; Carraway and Cantley, 1994) . The interactions between receptor tyrosine kinases and speci®c signaling proteins is in part governed by phosphorylation at particular tyrosine residues in the carboxyl terminus of these receptors (see Carter and Kung, 1994; Dougall et al., 1994) . Receptor autophosphorylation is therefore not only required for direct interaction and phosphorylation of protein substrates, but also is felt to be important in the regulation of the enzymatic tyrosine kinase activity.
In the case of EGFR, self-phosphorylation of the cytoplasmic domain is known to occur at ®ve tyrosine residues located in the carboxyl terminus outside of the enzymatic kinase domain (Y992, Y1068, Y1086, Y1148 and Y1173) (see Carter and Kung, 1994) . Many kinases are also activated by phosphorylation of a conserved Thr or Tyr site that lies within the catalytic core of the kinase domain. For example, a conserved tyrosine residue within the kinase domain of the v/c-src kinase has been located at position Y416 (Hanks et al., 1988) . Autophosphorylation of this site is important for regulating kinase enzymatic function and biological activity of the src kinase (Kmiecik and Shalloway, 1987; Piwnica et al., 1987) . The corresponding tyrosine residue is important for regulating kinase function in many other receptor and cytoplasmic tyrosine kinases, including v-fps (Weinmaster et al., 1984) , the insulin receptor (Ellis et al., 1986) , the colony stimulating factor I-receptor (CSF-IR) (Roussel et al., 1990; Van de Geer and Hunter, 1991) , and the platelet-derived growth factor receptor (PDGFR) (Fantl et al., 1989; Morrison et al., 1990) . However, the analogous site within the catalytic core of the EGFR kinase domain, Y845, has been reported to be less relevant for tyrosine autophosphorylation of the mature 170 kDa EGFR, EGF-induced stimulation of DNA synthesis, or EGFdependent transformation of NIH3T3 cells (Gotoh et al., 1992) . Nevertheless, mutations in charged residues adjacent to Y845 decrease the Vmax for receptor selfphosphorylation, suggesting that this surface region stabilizes the catalytic core of the kinase domain and is important for maximal self-phosphorylation activity of the kinase domain (Timms et al., 1995) . neu is also tyrosine-phosphorylated on ®ve sites, Y882, Y1028, Y1143, Y1226/7 and Y1253 (see Dougall et al., 1994) . Residue Y882 corresponds to position Y845 of the EGFR and we have deduced its position through molecular modeling of the kinase domain (Murali et al., 1996) . In order to address whether position Tyr-882 is important for p185 neu receptor autophosphorylation and transformation mediated by oncogenic p185
neu , we constructed a mutant neu cDNA encoding the rat neu activating transmembrane point mutation and a phenylalanine (F) residue at position 882 (Y882F). In another pair of mutants, we deleted the carboxyl terminal 122 amino acids which included the last three autophosphorylation sites in the carboxyl terminal (TAPstop) (Mikami et al., 1992) and also combined it with Y882F (Y882F/APstop). Tyr-882 residue appears important for both the regulation of enzymatic kinase function of p185 neu and for some downstream signaling events mediated by p185 neu receptors. These studies may facilitate the development of site-speci®c inhibitors of kinase activation which inhibit signal transduction events contributing to oncogenic transformation.
Results
Tyrosine autophosphorylation of oncogenic p185 neu (Tneu) and mutant neu derivatives in vivo Schematic representation of rat p185 neu and derived mutant protein structures are shown in Figure 1 . Tneu refers to the full-length oncogenic p185 neu receptor which contains the activating transmembrane point mutation (V664E). All mutant neu constructs were derived from Tneu and therefore contain the activating transmembrane point mutation. Site-directed mutagenesis was used on the Tneu construct to generate a phenylalanine (F) at position 882 instead of a tyrosine (Y). Tneu and Y882F were used to generate an additional set of mutants, TAPstop and Y882F/ APstop, respectively, by deleting 122 amino acids from the carboxyl terminus. Additionally, a mutant chimera, EGFR/Y882F, was generated from the EGFR/neu chimeric receptor. These mutant proteins were expressed in NR6 cells, a ®broblast cell line which lacks endogenous EGF receptors (Pruss and Herschman, 1977) . Stable cell lines expressing each mutant neu containing the transmembrane point mutation, V664E (*). Y882F has a phenylalanine substitution for tyrosine at the 882 residue. TAPstop and Y882F/APstop are derived from Tneu and Y882, respectively, by deleting 122 amino acid residues from carboxyl terminus (CT). EGFR/neu, a gift from K Alitalo (University of Helsinki), is a wild-type chimera containing the ectodomain and transmembrane region of EGFR, and the intracellular domain of p185 neu . The mutant chimera, EGFR/Y882F was derived from EGFR/neu and Y882F by subcloning. The number of potential tyrosine autophosphorylation sites for each mutant is also listed p185 neu : role of Y882 in transformation H-T Zhang et al constructs were established and designated as shown in Figure 1 . Immunoprecipitation of mutant p185 neu forms followed by immunoblotting with an anti-phosphotyrosine antibody was performed in order to assess whether substitution of tyrosine-882 was associated with a reduction in total phosphotyrosine content of oncogenic p185
neu immuno-complexes ( Figure 2 , lanes 1 ± 4). The same blot was stripped and re-probed with the anti-Neu antibody a-Bacneu to verify the receptor protein level (Figure 2 , lanes 5 ± 8). The phosphotyrosine content was estimated by scanning densitometry (not shown). Cells expressing Y882F (designated T882) appeared to have comparable levels of total phospho-tyrosine content of the receptor compared with oncogenic neu expressing cells (designated Tneu) ( Figure 2 , lanes 1 ± 2 and 5 ± 6). Comparable levels were also observed in a comparison between mutants TAPstop (TAPstop cells) and Y882F/APstop (TAP882 cells) (Figure 2 , lanes 3 ± 4 and 7 ± 8).
It is noteworthy that the mutant TAP882, although missing four out of ®ve known tyrosine phosphorylation sites, still exhibited a high phospho-tyrosine content ( Figure 2 , lane 4). This observation supports the notion that there exist some cryptic tyrosine phosphorylation sites other than the known ones of the erbB family of RTKs. Notably, replacing all the ®ve known sites in EGFR could not completely eliminate tyrosine phosphorylation of the receptor upon ligand stimulation (Decker, 1993; Li et al., 1994) .
In cells expressing the full-length p185 neu mutants (Tneu and T882 lines), an additional faster migrating form of the protein was observed which presumably represents a precursor form of p185 neu ( Figure 2 , lanes 1 ± 2 and 3 ± 4). We and others have noted these protein forms, particularly in quiescent cells expressing protooncogenic p185
neu (Kiyokawa et al., 1995) , and has been interpreted as a form of the receptor with altered phosphorylation of serine and/or threonine residues.
Our results indicate that this precursor form of p185 neu is also dierentially phosphorylated on tyrosine residues. The greater abundance of the tyrosine phosphorylated precursor form of Y882F may be of relevance to the biologic data described below. Deletion of the carboxyl-terminal 122 amino acids produced a protein of approximately 170 ± 175 kDa and resulted in the detection of only one form of mutant p185 neu receptor.
Eect of Y882F substitution on in vitro kinase activity of p185 neu is not signi®cantly changed by the substitution of tyrosine-882 with phenylalanine. Cell lysates were prepared from cell lines indicated above (Figure 1 ) and were subjected to immunoprecipitation using anti-neu mAb 7.16.4. The protein samples were separated by 6% SDS ± PAGE and transferred onto nitrocellulose membranes followed by immunoblotting with anti-phosphotyrosine antibody pY20 (Santa Cruz) (a) or the anti-p185 neu antibody Bacneu (b). All protein signals were visualized using the enhanced chemiluminescence (ECL) technique (Amersham). Molecular weight markers (in kDa) are indicated on the right of the panel and the positions of full length (p185) and truncated p185 neu proteins are shown (arrow). The slightly high-mobility precursor forms of full length neu proteins (lanes 1, 2, 5 and 6) were also denoted (*) To analyse mitogenic signaling in response to ligand, the intracellular domains of p185 neu and Y882F were independently fused with the extracellular domain of the EGF receptor (Figure 1 ). Using the MTT assay, we determined that the proliferation of cell lines expressing these chimeric receptors was EGF-dependent ( Figure  4) . We had previously shown that the EGF dose needed for a proliferative response to ligand-induced DNA synthesis or cell proliferation (O'Rourke et al., 1997) was in the ng/ml range in ®broblasts and human transformed cell lines expressing EGFR only. In the presence of EGF (1 ± 50 ng/ml), the growth of Er/882 cells expressing EGFR/Y882F chimeric receptors was less than those expressing EGFR/neu receptors (Er/neu cell line) (Figure 4 ). At a concentration of 100 ng/ml, EGF mediated an inhibitory eect on the growth of Er/neu cells, which we previously observed in ®broblasts expressing high levels of human EGFR . However, this high EGF dose had no similar in¯uence on Er/882 cells, indicating that some regulatory mechanism was impaired by the Y882F mutation. As a negative control, a chimeric construct with all ®ve tyrosine phosphorylation sites replaced was also transfected into ®broblasts, which, not unexpectedly, responded only modestly to EGF stimulation (data not shown).
Substitution of Y882 inhibits transformation of cell lines expressing oncogenic p185
neu and EGFR/neu chimeric receptors. Anchorage-independent cell growth
The ability of murine ®broblasts to form colonies in soft agar was addressed in order to determine whether tyrosine-882 was relevant to the transforming activity of p185 neu . As is shown in Figure 5 (and Table 1 ), cells expressing Y882F were inhibited in their transforming Figure 4 MTT assay: response of dierent cell lines to EGF treatment. On day 1, individual 96-well plates were seeded with 5000 cells/well of cells expressing EGFR/neu or EGFR/Y882F mutant receptors in 5% FBS medium and incubated overnight at 378C. On day 2, the medium was changed to serum-free medium with dierent concentration of EGF and the microplates were incubated at 378C for 48 h. On day 4, MTT was added (1 mg/ml) and after 4 h incubation at 378C, cells were lysed by buer containing SDS and DMSO at pH 4.7. The OD was then measured on day 5 at 600 nm using an ELISA reader Tneu TAPstop Er/neu T882 TAP882 Er/882 Figure 5 Colony growth in soft agar. Two hundred and ®fty cells of each line were seeded in soft agar dishes and fed with 5% FBS-DMEM with (EGFR/neu and EGFR/882F) or without (Tneu, Y882F, TAPstop, and Y882F/APstop) EGF (10 ng/ml) twice a week for 3 weeks. Colonies were then visualized after staining with p-iodnitrotetrazolium violet (1 mg/ml) and counted b Cells were treated with 10 ng/ml EGF as described in Materials and methods p185 neu : role of Y882 in transformation H-T Zhang et al eciency in vitro. Elimination of the three carboxyl terminal autophosphorylation sites (TAPstop) resulted in reduced oncogenicity relative to full-length oncogenic Tneu which was further reduced by substituting tyrosine-882 with phenylalanine (Y882F/APstop). In order to assess the eect of tyrosine-882 substitution on ligand-dependent transformation, EGFR/neu and EGFR/882 chimeric proteins were expressed in murine ®broblasts. When these cells were examined for their growth capability, colony growth in soft agar of EGFdependent ®broblasts was inhibited by the Y882F substitution in the p185 neu intracellular region. The in vitro transforming activity of Tneu and Y882F were also examined by an assay of focus formation in mass culture. In this study, signi®cantly less foci were observed in Y882F-transfected cells (data not shown). These data con®rmed that the Y882F mutant had a reduced transforming activity.
In vivo tumorigenicity
A comparison of tumor growth in athymic mice was then performed with the Y882F mutant cell lines. Oncogenic p185 neu -expressing ®broblasts (Tneu) form rapidly growing tumors when implanted subcutaneously in nude mice (Figure 6 ). Full-length Y882F mutant receptors are inhibited in their ability to mediate transformation in vivo (Figure 6a) . Deletion of the carboxyl terminal three autophosphorylation sites in p185 neu proteins containing the activating transmembrane point mutation (TAPstop) resulted in a signi®cant diminution of tumor forming eciency (Figure 6b ). Visible tumor growth did not occur in these animals until 4 weeks, which was beyond the time point that animals implanted with Tneu cells (Qian et al., 1996) were sacri®ced from tumor burden. Again, substitution of tyrosine-882 was associated with further inhibition of transforming eciency in vivo (Figure 6b ).
Discussion
Dimerization of erbB family receptors results in activation of the enzymatic kinase by an incompletely understood intermolecular allosteric mechanism (Ullrich and Schlessinger, 1990; Wada et al., 1990) , although an intramolecular mechanism contributing to kinase activation has not been excluded (Groenen et al., 1997) . It is thought that contacts in the ectodomain in erbB family receptors initiate the formation of dimers thereby bringing the kinase domains in proximity with one another, which is required for catalytic activation (Weiner et al., 1989; Ullrich and Schlessinger, 1990) . The use of dominant-negative mutant receptors has established that ectodomain interactions alone are sucient for erbB family homo-and heterodimerization O'Rourke et al., 1997) , although cytoplasmic interactions determine receptor signaling outcome (Qian et al., 1995) . Using co-immunoprecipitation experiments, truncated EGFRs lacking the extracellular region were shown to oligomerize with holo-EGFRs, resulting in constitutively phosphorylated receptors (Chantry, 1995) . Deletion analysis showed that intracellular contacts within the kinase domain were most important in these interactions. Kinase domain oligomerization was also suggested to occur between truncated EGFRs and HER2/neu (Chantry, 1995) , which was predicted by molecular modeling (Murali et al., 1996) . The carboxyl terminal autophosphorylation sites in the EGFR (Y1086, Y1148 and Y1173) are not required for enzymatic kinase activation (Walton et al., 1990) . The structural requirements and regulation of kinase domain interactions necessary for catalytic activation and transphosphorylation of substrates have not been de®ned.
Protein kinases share a high degree of homology in the catalytic domain, whether they are serine/threonine kinases or tyrosine kinases (Hanks et al., 1988) . p185 neu and EGFR, members of the erbB family of type I RTKs, share 82% amino acid homology in the tyrosine kinase domain (Murali et al., 1996) . In contrast, the carboxyl terminus of the cytoplasmic domain is not signi®cantly conserved within tyrosine kinase receptor families. The kinase domain of erbB family kinases can be subdivided into an ATP-binding domain, an neu : role of Y882 in transformation H-T Zhang et al activation loop, and a catalytic domain (Knighton et al., 1991; Murali et al., 1996) . The ATP-binding domain is more conserved between kinase family members than the catalytic domain. Interestingly, the most variable region within the kinase domain is the activation loop where the autophosphorylation tyrosines are located. The activation loop may be critical for permitting access to dierent substrates and facilitating subsequent attachment.
Molecular modeling of the kinase domains of EGFR and p185
neu reveals that the orientation of the tyrosines within the activation loop, tyrosine-845 and tyrosine-882, respectively, are oriented dierently, which might account for the dierent phenotypic consequences of substitution of these residues in the corresponding receptors (Murali et al., 1996) . It has been reported that Y845 is not required for either the tyrosine autophosphorylation of the mature 170 kDa EGFR, the initiation of EGF-induced DNA synthesis, or for EGF-dependent transformation of NIH3T3 cells (Gotoh et al., 1992) . However, mutations in charged residues adjacent to Y845 decrease the Vmax for receptor self-phosphorylation, suggesting that these residues stabilize the catalytic core of the kinase domain and are important for maximal self-phosphorylation activity of the kinase domain.
Although both tyrosines within the activation loop (Y845 in EGFR and Y882 in p185 in the EGFR loop alters this negatively charged structural feature. It has been reported this basic residue prevented peptides derived from the activation loop of EGFR from being phosphorylated by some protein tyrosine kinases (Cola et al., 1989) . However, in p185 neu , T 880 at the corresponding position should not in¯uence this structural feature, thus making the activation loop accessible for p185 neu or other tyrosine kinases capable of phosphorylating Y882. These dierences between EGFR and p185 neu may account for the dierent biological eects of similar mutations on EGFR and p185 neu (Y845F and Y882F, respectively). In our studies, substitution of tyrosine-882 in the full-length oncogenic p185 neu receptor did not appreciably alter the level of tyrosine phosphorylation of p185 neu in vivo. This observation supports the notion of cryptic or supplemental phosphotyrosine sites in EGFR and p185 neu . It has been reported that replacing all the identi®ed tyrosine autophosphorylation sites in EGFR did not completely eliminate tyrosine phosphorylation of EGFR upon EGF stimulation, or EGF stimulation of mitogen-activated protein kinase activity (Decker, 1993) . In our experiments, in vivo tyrosine phosphorylation was detected in the mutant with deletion of four autophosphorylation sites (Y882F/ APstop). Although the in vitro kinase activity for p185 neu receptor self-phosphorylation and phosphorylation of exogenous substrate was decreased in all cell lines expressing Y882F, other kinases or signaling molecules could be involved to account for our inability to detect receptor phosphotyrosine content dierences at this level of analysis.
Germline mutations in the tyrosine kinase domain of the RET proto-oncogene, in particular a Met-4Thr substitution at position 918, are associated with the familial cancer syndrome multiple endocrine neoplasia (MEN) type 2B (Carlson et al., 1994; Hofstra et al., 1994) . M918T has been shown to be an activating mutation by altering the substrate speci®city in the tyrosine kinase domain of RET (Santoro et al., 1995) . A shift in the substrate speci®city which would be transforming in certain tissues depending on the dierentially expressed pro®le of available substrates capable of regulating RET catalytic activity. Position 918 in RET is located in the substrate binding domain of the activation loop, and is predicted by homology modeling to be approximately 15A Ê from a tyrosine analogous to Y882 in p185 neu . Mutation of tyrosine-882 was associated with a diminution of transforming eciency mediated by oncogenic p185 neu in vitro and in vivo. Upon ligand stimulation, the erbB family of RTKs transduce signals by creating: (1) an active form of tyrosine kinases which can phosphorylate signaling molecules including the receptor per se; (2) phosphorylated tyrosines as docking sites for SH2/SH3 domain containing proteins. It is unlikely that Y882 acts as one docking site, since there is no homology in this region to SH2 or SH3 binding motif and this site has never been shown able to associate with other molecules. Our data suggest that Y882 plays an important role in the transforming potential and tumorigenicity of oncogenic p185
neu by regulating the kinase activity of this receptor tyrosine kinase. By having a distinct phosphorylation status, Y882 could alter the accessibility of particular substrates to the kinase catalytic cleft. In support of this, we found that some proteins are not phosphorylated in the in vitro kinase assay as a result of the Y882F substitution (Figure 3) , although the identities of these potential substrates are not known at present.
The corresponding residue in EGFR, Y845, has been found phosphorylated by c-Src in an EGFdependent manner both in vivo and in vitro (Sato et al., 1995) . Further examination of the structural features of p185 neu and EGFR kinase domain activation may facilitate the understanding of cross-talking between signaling pathways and the development of site-speci®c inhibitors of erbB receptor catalytic function contributing to oncogenesis.
Materials and methods

Construction of mutants and expression vectors, and derivation of stably transfected cell lines
All the following mutant p185 neu cDNAs were derived from rat oncogenic neu cDNA (Tneu) containing a single mutation (V664E) in the transmembrane region. Brie¯y, the mutant Y882F was derived from Tneu by site-directed mutagenesis by substituting a phenylalanine for Tyrosine-882. The TAP/stop mutant was also made by site-directed mutagenesis by introducing a stop codon at position 1139, which was 122 amino acids from the carboxyl terminus (Mikami et al., 1992) . The T882F/APstop mutant was made by a subcloning strategy to generate both the Y882F substitution and carboxyl terminal deletion. To make a chimeric mutant of EGFr and TneuY882F, a 6.7 kb SalI ± XbaI fragment from an EGFR-neu expression vector, pSV2EGFR/neu (Lehvaslaiho et al., 1989) , was ligated to a 2.3 kb fragment containing the 3' region of the Y882F mutant. All the mutant constructs were veri®ed by DNA sequencing.
The wild type or mutant neu cDNAs were subcloned into the pMuLVLTRneo r expression vector and then transfected into NR6 ®broblasts lacking endogenous EGFRs with neomycin selection to generate mutant neu-expressing subclones. The expression of mutant neu proteins in resultant colonies was con®rmed by¯ow cytometry using an anti-p185 neu monoclonal antibody (mAb) 7.16.4 . The resultant transfected cell lines were designated Tneu(T-2), T882, TAP/stop, TAP882, Er/neu and Er/882 (Figure 1) . Using¯ow cytometric analysis, it was determinated that neu-derived proteins were expressed at comparable levels in Tneu and T882 cells, and in TAP/stop and TAP882 cells, although the latter two cell lines had higher surface expression levels than the Tneu and T882 cell lines. These transfected clones were maintained in Dulbecco's Modi®ed Eagle's medium (DMEM) containing 5% fetal bovine serum (FBS, Hyclone).
Analysis of transforming characteristics
Anchorage-independent growth was determined by assessing the colony forming eciency of cells suspended in soft agar (O'Rourke et al., 1997) . Cells (250 ± 1000) were suspended in 0.18% agarose/5% FBS-DMEM and plated on 0.25% of basal agar in 60 mm tissue culture plates. 0.5 ml of DMEM medium (5% FBS, 20 mM HEPES, pH 7.5) was added to soft-agar cultures once a week for the duration of the experiment. Colonies (40.3 mm) were visualized on day 21 for all cell lines after staining with piodnitrotetrazolium violet (1 mg/ml). Each cell line was examined in triplicate for three separate experiments. Number of colonies reported represented the mean of triplicate samples.
To analyse tumor growth in athymic mice, cells (1610 6 ) of each line were suspended in 0.1 ml of PBS and injected intradermally in the mid-dorsum of NCR nude mice. PBS alone was also injected as a control. Animals used in this study were maintained in accordance with the guidelines of the Committee on Animals of the University of Pennsylvania and those prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resource. Tumor growth was monitored every 2 ± 3 days up to 8 weeks. Tumor size was calculated by this formula: 3.14/ 66(length6width6thickness).
Antibodies
The monoclonal antibody (mAb) 7.16.4 against the ectodomain of p185 neu was produced from hybridoma cells as described previously (Drebin et al., 1984) . The polyclonal rabbit antiserum reactive with the neu intracellular domain, designated anti-Bacneu, was also utilized . A monoclonal anti-phosphotyrosine antibody (pY20) was purchased from Santa Cruz, Biotechnology (Santa Cruz, CA).
In vitro kinase assay
Cells were plated in 100 mm culture dishes and the next day were washed twice in ice cold PBS and lysed in 1 ml of lysis buer (50 mM Hepes, pH 7.5, 150 mM NaCl, 3% Brij-35, 2 mM EDTA, 0.02 mg/ml Aprotinin, 10% glycerol, 1.5 mM MgCl 2 ). Cell lysates were centrifuged at 20 000 g for 15 min. Protein concentrations of cell lysate were measured with the Dc Protein Assay (Bio-Rad). Lysates that contained comparable amounts of neu-derived proteins (as determined by Western blotting) were used for immunoprecipitation with the anti-neu mAb, 7.16.4. 40 ml of 50% (vol/vol) protein A-sepharose were used to collect the immune complexes, which were then washed three times with wash buer (50 mM HEPES, 150 mM NaCl, 0.1% Brij-35, 2 mM EDTA, 0.01 mg/ml Aprotinin, 0.03 mM Na 3 VO 4 ). The pellets were suspended in 20 ml of 20 mM HEPES (pH 7.4, 5 mM MnCl 2 , 0.1% Brij-35, 0.03 mM Na 3 VO 4 , 0.02 mg/ml Aprotinin) containing 5 mCi of [g 32 P]ATP, and incubated at room temperature for 30 min. The reaction were terminated by the addition of 36electrophoresis sample buer containing 2 mM ATP. After incubation at 1008C for 3 min, samples were then analysed by SDS ± PAGE.
MTT (3,(4,5-dimethylthiazol-2-yl)2,5-diphenyl-tetrazolium bromide) assay of cell proliferation
The MTT assay for measuring cell growth has been reported previously (Hansen et al., 1989) . Brie¯y, cells (5000) of each cell line were seeded in 96-well plates overnight in DMEM containing 5% FBS. Cells were starved in ITS-DMEM for 48 h, then cultured in 100 ml of the same medium plus various concentrations of EGF for 48 h. 25 ml of MTT solution (5 mg/ml in PBS) were added to each well, and after 2 h of incubation at 378C, 100 microliters of the extraction buer (20% w/v of SDS, 50% N,N-dimethyl formamide, pH 4.7) was added. After an overnight incubation at 378C, the optical density at 600 nm were measured using an ELISA reader. Each value represented a mean of four samples.
